Understanding drug addiction: a neuropsychological perspective.
The purpose of the present review is to describe the neuropsychological correlates of long-term substance abuse and to discuss the findings within the context of premorbid vulnerabilities, comorbidity and adolescent neurodevelopment. The authors critically review key findings from the neuropsychological literature related to the long-term sequelae of alcohol, cannabis, inhalant, opiates, psychostimulants and ecstasy use. Leading electronic databases such as PubMed were searched to identify relevant studies published in the past 20 years. References identified from bibliographies of pertinent articles and books in the field were also collected and selectively reviewed. Across substances, individuals with long-term abuse consistently demonstrate neuropsychological impairments of executive (inhibitory) control, working memory and decision making, together with neurobiological abnormalities involving frontotemporal and basal ganglia circuits. In some instances these deficits are dose dependent, implying that they are a direct consequence of prolonged drug exposure. However, comorbid behavioural, personality and mental health problems are common among drug-using populations and are associated with similar neuropsychological deficits. Presented herein is a neuropsychological model of addictive behaviour that highlights the complex interplay between cognition, brain maturation, psychopathology and drug exposure.
Yücel
Murat
M
ORYGEN Research Centre, Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia. murat@unimelb.edu.au
Lubman
Dan I
DI
Solowij
Nadia
N
Brewer
Warrick J
WJ
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000437:Alcoholism / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D000701:Analgesics, Opioid / Q000009:adverse effects; D016739:Behavior, Addictive / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000009:adverse effects; D003072:Cognition Disorders / Q000175:diagnosis* / Q000453:epidemiology / Q000523:psychology; D015897:Comorbidity; D006801:Humans; D002189:Marijuana Abuse / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects; D009483:Neuropsychological Tests / Q000706:statistics & numerical data*; D009293:Opioid-Related Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology
D000701:Analgesics, Opioid; D000697:Central Nervous System Stimulants; D018817:N-Methyl-3,4-methylenedioxyamphetamine